The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

Full Deal Summary

Respiratory device maker Vapotherm Inc. netted $52.1mm in its initial public offering of 4mm shares at $14 each, the low end of its anticipated $14-16 range.

Vapotherm plans to use $37mm of the proceeds to hire sales and marketing personnel and expand marketing programs in the US and internationally, and $11mm for R&D activities. The company’s Hi-VNI technology uses a small-bore nasal interface to deliver heated, humidified, and oxygenated air at a high speed to patients with respiratory diseases. At the beginning of 2018, Vapotherm reported results from a controlled trial stating Hi-VNI is the only high-flow nasal cannula approach that’s as clinically effective as non-invasive positive pressure ventilation for patients experiencing undifferentiated respiratory distress. The technology has been incorporated into the firm’s Precision Flow systems. At the end of September the firm had $13.2mm in cash.

+ Show All | – Hide All


Click a figure for comparable deals.

Potential Deal Value $52.08mm
Transactions 1 of 1 (11/2018)
Equity $52.08mm
Total Line Value $52.08mm
Price/Share $14.00
# Shares 4mm
Shares Outstanding 16.73mm
Post-Money Valuation $234.26mm
Gross Proceeds $56.00mm
Net Proceeds $52.08mm
Private Money Raised $165.06mm
Total Shareholders Equity -$155.92mm
Net Profit/Loss -$201.51mm
Cash On Hand $13.20mm

Deal Information

Click a keyword for comparable deals.

Deal Industry Medical Devices
Deal Status Final
Deal Type Financing

Company Information

Click a keyword for comparable companies.

Vapotherm Inc. | Ticker: VAPO
View Company Profile | View Company Deals
Company Location Worldwide
North America
Industry Medical Devices
Ownership Public
Therapeutic Area(s) of Focus Respiratory, Pulmonary
Company Advisors (Underwriters) Bank of America Merrill Lynch
Canaccord Genuity Inc.
William Blair & Co.